Sign in →

Test Code 5081 Parathyroid Hormone-Related Peptide (PTHrP), Plasma

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Plasma EDTA

Specimen Required

Patient Preparation: None required

Collection Container/Tube: Ice-cooled, lavender top (EDTA)

Submission Container/Tube: Plastic vial

Specimen Volume: 0.7 mL

Collection Instructions: Spin specimen down in a refrigerated centrifuge or in chilled centrifuge cups.

Specimen Minimum Volume

0.25 mL

Specimen Stability Information

Specimen Type Temperature Time
Plasma EDTA Frozen 90 days

Reference Values

<2.0 pmol/L

Day(s) and Time(s) Performed

Monday, Wednesday, Thursday ; 2 p.m.


Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
PTHRP PTH-Related Peptide 15087-0


Result ID Test Result Name Result LOINC Value
81774 PTH-Related Peptide 15087-0

Clinical Information

Hypercalcemia of malignancy is a common cause of hypercalcemia in hospitalized patients. Hypercalcemia of malignancy is typically not due to excess parathyroid hormone (PTH). In these disorders, PTH is usually suppressed due to elevated serum calcium concentrations. A variety of other mechanisms lead to inappropriate hypercalcemia in hypercalcemia of malignancy. These include:

-Impaired renal function due to a tumor or its treatment

-Osteolytic activity within bony metastases

-Release of calcemic cytokines by non-osteolytic bony metastases

-Ectopic 1-alpha hydroxylase activity in tumor tissues

-Secretion of humoral factors mimicking PTH action (humoral hypercalcemia of malignancy: HHM), usually associated with secretion of parathyroid hormone-related peptide (PTHrP) by the primary tumor (or more commonly its metastases)

-Other as yet unknown factors


Frequently, a single cause cannot be pinpointed. Amongst the defined causes of the condition, PTHrP secretion is believed to be the most common culprit.


PTHrP is a single monomeric peptide that exists in several isoforms, ranging from approximately 60 amino acids to 173 amino acids in size, which are created by differential splicing and posttranslational processing by prohormone convertases. PTHrP is produced in low concentrations by virtually all tissues. The physiological role of PTHrP remains incompletely understood. Its functions can be broadly divided into 5 categories, not all of which are present in all PTHrP isoforms or in all tissues:

-Transepithelial calcium transport, particularly in the kidney and mammary gland

-Smooth muscle relaxation in the uterus, bladder, gastrointestinal tract, and arterial wall

-Regulation of cellular proliferation

-Cellular differentiation and apoptosis of multiple tissues

-As an indispensable component of successful pregnancy and fetal development (embryonic gene deletion is lethal in mammals)


PTHrP's diverse functions are mediated through a range of different receptors, which are activated by different portions of PTHrP. Among the many receptors that respond to PTHrP is the PTH receptor, courtesy of the fact that 8 of the 13 N-terminal amino acids of PTH and of 3 common PTHrP isoforms are identical. Since most of PTHrP's actions in normal physiology are autocrine or paracrine, with circulating levels being very low, this receptor cross-talk only becomes relevant when there is extreme and sustained overproduction of PTHrP. This is seen occasionally in pregnancy, lactation and, rarely, in a variety of nonmalignant diseases. However, it is most commonly observed when tumors secrete PTHrP ectopically. In rough correlation with physiological production levels of PTHrP in the corresponding healthy tissues, ectopic PTHrP production is most commonly seen in carcinomas of breast, lung (squamous), head and neck (squamous), kidney, bladder, cervix, uterus, and ovary. Neuroendocrine tumors may also occasionally produce PTHrP. Most other carcinomas, sarcomas, and hematolymphatic malignancies only sporadically produce PTHrP, with the notable exceptions of T-cell lymphomas and myeloma.


Patients with HHM may have increased PTHrP values before treatment. PTHrP level decreases and PTH level increases, accompanied by decreased serum calcium values, with successful treatment.


Depending on the patient population, up to 80% of patients with malignant tumors and hypercalcemia will be suffering from humoral hypercalcemia of malignancy (HHM). Of these, 50% to 70% might have an elevated parathyroid hormone-related peptide (PTHrP) level. These patients will also usually show typical biochemical changes of excess parathyroid hormone (PTH)-receptor activation, namely, besides the hypercalcemia, they might have hypophosphatemia, hypercalcuria, hyperphosphaturia, and elevated serum alkaline phosphatase. Their PTH levels will typically be less than 30 pg/mL or undetectable.


In patients with biochemical findings that suggest, but do not prove, primary hyperparathyroidism (eg, hypercalcemia, but normal or near-normal serum phosphate, and a PTH level that is within the population reference range but above 30 pg/mL), HHM should be considered as a diagnostic possibility, particularly if the patient is elderly, has a history of malignancy, or risk factors for malignancy. An elevated PTHrP level in such a patient is highly suggestive of HHM as the cause for the hypercalcemia.

Clinical Reference

1. Burtis WJ: Parathyroid hormone-related protein: structure, function and measurement. Clin Chem 1992;38(11):2171-2183

2. Wysolmerski JJ, Stewart AF: The physiology of parathyroid hormone-related protein: an emerging role as a developmental factor. Annu Rev Physiol 1998;60:431-460

3. Guise TA, Mundy GR: Cancer and bone. Endocr Rev 1998;19(1):18-54

4. Clemens TL, Cormier S, Eichinger A, et al: Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets. Br J Pharmacol 2001;134(6):1113-1136

5. Jacobs TP, Bilezikian JP: Clinical Review: Rare causes of hypercalcemia. J Clin Endocrinol Metab 2005;90(11):6316-6322

6. Wu TJ, Lin CL, Taylor RL, et al: Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma. Mayo Clin Proc 1997;72(12):1111-1115

Method Name

Immunochemiluminometric Assay (ICMA)